Travere Therapeutics, Inc. - Common Stock (TVTX)

According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved.

Two analysts waxed bullish on the future of the company.

Travere Therapeutics (TVTX) shows strong earnings momentum, a bullish technical uptrend, and a current consolidation phase, presenting a potential breakout setup for growth investors.

Travere Therapeutics (TVTX) shows strong high-growth momentum with surging sales and a positive technical setup, signaling a potential breakout.

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,

The stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug.

Travere Therapeutics (TVTX) Q3 2025 earnings crush expectations, driven by strong FILSPARI sales. Revenue soared 160% year-over-year, sparking an 11.7% stock surge.

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.

Travere Therapeutics (TVTX) shows strong growth momentum with accelerating earnings and revenue. Its high technical rating and clear setup pattern offer a compelling investment case.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Shares shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug.